{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T08:30:10Z","timestamp":1793262610035,"version":"4.5.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T00:00:00Z","timestamp":1617753600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Assist Reprod Genet"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s10815-021-02181-6","type":"journal-article","created":{"date-parts":[[2021,4,7]],"date-time":"2021-04-07T11:03:34Z","timestamp":1617793414000},"page":"1897-1908","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Fertility considerations in targeted biologic therapy with tyrosine kinase inhibitors: a review"],"prefix":"10.1007","volume":"38","author":[{"given":"Anupama","family":"Rambhatla","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Strug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica Garcia","family":"De Paredes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcos I.","family":"Cordoba Munoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3281-7085","authenticated-orcid":false,"given":"Mili","family":"Thakur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,7]]},"reference":[{"issue":"14","key":"2181_CR1","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/nejm200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001;344(14):1031\u20137. https:\/\/doi.org\/10.1056\/nejm200104053441401.","journal-title":"N Engl J Med"},{"issue":"16","key":"2181_CR2","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1200\/jco.2014.59.7344","volume":"33","author":"A Cioffi","year":"2015","unstructured":"Cioffi A, Maki RG. GI stromal tumors: 15 years of lessons from a rare cancer. J Clin Oncol. 2015;33(16):1849\u201354. https:\/\/doi.org\/10.1200\/jco.2014.59.7344.","journal-title":"J Clin Oncol"},{"issue":"2","key":"2181_CR3","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1200\/jco.2017.74.9705","volume":"36","author":"M von Mehren","year":"2018","unstructured":"von Mehren M, Joensuu H. Gastrointestinal stromal tumors. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(2):136\u201343. https:\/\/doi.org\/10.1200\/jco.2017.74.9705.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"48","key":"2181_CR4","doi-asserted-by":"publisher","first-page":"7906","DOI":"10.1038\/sj.onc.1208160","volume":"23","author":"SJ Parsons","year":"2004","unstructured":"Parsons SJ, Parsons JT. Src family kinases, key regulators of signal transduction. Oncogene. 2004;23(48):7906\u20139. https:\/\/doi.org\/10.1038\/sj.onc.1208160.","journal-title":"Oncogene"},{"issue":"17","key":"2181_CR5","doi-asserted-by":"publisher","first-page":"5546","DOI":"10.1158\/1078-0432.Ccr-10-2616","volume":"17","author":"JC Montero","year":"2011","unstructured":"Montero JC, Seoane S, Oca\u00f1a A, Pandiella A. Inhibition of SRC family kinases and receptor tyrosine kinases by dasatinib: possible combinations in solid tumors. Clin Cancer Res. 2011;17(17):5546\u201352. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-10-2616.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2181_CR6","doi-asserted-by":"publisher","first-page":"363","DOI":"10.3109\/10428190903518295","volume":"51","author":"DJ DeAngelo","year":"2010","unstructured":"DeAngelo DJ, Attar EC. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice. Leuk Lymphoma. 2010;51(3):363\u201375. https:\/\/doi.org\/10.3109\/10428190903518295.","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2181_CR7","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol. 2020;95(6):691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792.","journal-title":"Am J Hematol"},{"issue":"8","key":"2181_CR8","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1080\/17474086.2016.1205479","volume":"9","author":"E Abruzzese","year":"2016","unstructured":"Abruzzese E, Trawinska MM, de Fabritiis P, Baccarani M. Management of pregnant chronic myeloid leukemia patients. Expert Rev Hematol. 2016;9(8):781\u201391. https:\/\/doi.org\/10.1080\/17474086.2016.1205479.","journal-title":"Expert Rev Hematol"},{"issue":"10","key":"2181_CR9","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/j.leukres.2013.07.020","volume":"37","author":"L Zhou","year":"2013","unstructured":"Zhou L, You JH, Wu W, Li JM, Shen ZX, Wang AH. Pregnancies in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitor. Leuk Res. 2013;37(10):1216\u201321. https:\/\/doi.org\/10.1016\/j.leukres.2013.07.020.","journal-title":"Leuk Res"},{"issue":"12","key":"2181_CR10","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.6004\/jnccn.2016.0162","volume":"14","author":"A Pallera","year":"2016","unstructured":"Pallera A, Altman JK, Berman E, Abboud CN, Bhatnagar B, Curtin P, et al. NCCN guidelines insights: chronic myeloid leukemia, Version 1.2017. J Natl Compr Cancer Netw. 2016;14(12):1505\u201312. https:\/\/doi.org\/10.6004\/jnccn.2016.0162.","journal-title":"J Natl Compr Cancer Netw"},{"issue":"1","key":"2181_CR11","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ygyno.2007.09.017","volume":"108","author":"S Chu","year":"2008","unstructured":"Chu S, Alexiadis M, Fuller PJ. Expression, mutational analysis and in vitro response of imatinib mesylate and nilotinib target genes in ovarian granulosa cell tumors. Gynecol Oncol. 2008;108(1):182\u201390. https:\/\/doi.org\/10.1016\/j.ygyno.2007.09.017.","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2181_CR12","doi-asserted-by":"publisher","first-page":"137","DOI":"10.4274\/tjh.2016.0092","volume":"34","author":"G Cengiz Seval","year":"2017","unstructured":"Cengiz Seval G, \u00d6zkavuk\u00e7u S, Seval M, Ayl\u0131 M. Gonadotoxic effects of nilotinib in chronic myeloid leukemia treatment dose in a mouse model. Turk J Hematol. 2017;34(2):137\u201342. https:\/\/doi.org\/10.4274\/tjh.2016.0092.","journal-title":"Turk J Hematol"},{"issue":"6","key":"2181_CR13","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1007\/s10815-020-01778-7","volume":"37","author":"W Salem","year":"2020","unstructured":"Salem W, Ho JR, Woo I, Ingles SA, Chung K, Paulson RJ, et al. Long-term imatinib diminishes ovarian reserve and impacts embryo quality. J Assist Reprod Genet. 2020;37(6):1459\u201366. https:\/\/doi.org\/10.1007\/s10815-020-01778-7.","journal-title":"J Assist Reprod Genet"},{"issue":"1","key":"2181_CR14","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.ydbio.2007.03.024","volume":"306","author":"LK McGinnis","year":"2007","unstructured":"McGinnis LK, Albertini DF, Kinsey WH. Localized activation of Src-family protein kinases in the mouse egg. Dev Biol. 2007;306(1):241\u201354. https:\/\/doi.org\/10.1016\/j.ydbio.2007.03.024.","journal-title":"Dev Biol"},{"issue":"2","key":"2181_CR15","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.ydbio.2008.11.038","volume":"327","author":"LK McGinnis","year":"2009","unstructured":"McGinnis LK, Kinsey WH, Albertini DF. Functions of Fyn kinase in the completion of meiosis in mouse oocytes. Dev Biol. 2009;327(2):280\u20137. https:\/\/doi.org\/10.1016\/j.ydbio.2008.11.038.","journal-title":"Dev Biol"},{"issue":"10","key":"2181_CR16","doi-asserted-by":"publisher","first-page":"1422","DOI":"10.1634\/theoncologist.2011-0137","volume":"16","author":"AM Zamah","year":"2011","unstructured":"Zamah AM, Mauro MJ, Druker BJ, Oktay K, Egorin MJ, Cedars MI, et al. Will imatinib compromise reproductive capacity? Oncologist. 2011;16(10):1422\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2011-0137.","journal-title":"Oncologist"},{"issue":"4","key":"2181_CR17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152872","volume":"11","author":"V Bernard","year":"2016","unstructured":"Bernard V, Bouilly J, Kramer P, Carr\u00e9 N, Schlumberger M, Visser JA, et al. The tyrosine kinase inhibitor sunitinib affects ovulation but not ovarian reserve in mouse: a preclinical study. PLoS One. 2016;11(4):e0152872. https:\/\/doi.org\/10.1371\/journal.pone.0152872.","journal-title":"PLoS One"},{"key":"2181_CR18","doi-asserted-by":"publisher","unstructured":"Cortes JE, Gambacorti-Passerini C, Deininger M, Abruzzese E, DeAnnuntis L, Br\u00fcmmendorf TH. Pregnancy outcomes in patients treated with bosutinib. International journal of hematologic oncology 9 (2):Ijh26. 2020. https:\/\/doi.org\/10.2217\/ijh-2020-0004.","DOI":"10.2217\/ijh-2020-0004"},{"key":"2181_CR19","unstructured":"US FDA bosulif (bosutinib) prescribing information. 2017. https:\/\/www.accessdata.fda.gov\/drugsatfdadocs\/label\/2017\/203341s009lbl.pdf. Accessed 17 Feb 2021."},{"issue":"12","key":"2181_CR20","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1002\/ajh.24186","volume":"90","author":"JE Cortes","year":"2015","unstructured":"Cortes JE, Abruzzese E, Chelysheva E, Guha M, Wallis N, Apperley JF. The impact of dasatinib on pregnancy outcomes. Am J Hematol. 2015;90(12):1111\u20135. https:\/\/doi.org\/10.1002\/ajh.24186.","journal-title":"Am J Hematol"},{"issue":"6","key":"2181_CR21","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1634\/theoncologist.2017-0381","volume":"23","author":"S Gazdaru","year":"2018","unstructured":"Gazdaru S, Perey L, Rosselet A, Mathevet P, Chalandon Y, Vulliemoz N. Successful ovarian stimulation for fertility preservation in a patient with chronic myeloid leukemia: switch from nilotinib to interferon-\u03b1. Oncologist. 2018;23(6):719\u201321. https:\/\/doi.org\/10.1634\/theoncologist.2017-0381.","journal-title":"Oncologist"},{"issue":"10","key":"2181_CR22","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1056\/NEJMc0707841","volume":"358","author":"C Christopoulos","year":"2008","unstructured":"Christopoulos C, Dimakopoulou V, Rotas E. Primary ovarian insufficiency associated with imatinib therapy. N Engl J Med. 2008;358(10):1079\u201380. https:\/\/doi.org\/10.1056\/NEJMc0707841.","journal-title":"N Engl J Med"},{"issue":"1","key":"2181_CR23","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2020.005","volume":"12","author":"Y Furukawa","year":"2020","unstructured":"Furukawa Y, Takahashi T, Suganuma R, Ohara M, Ota K, Kyozuka H, et al. Successful planned pregnancy through vitrified-warmed embryo transfer in a woman with chronic myeloid leukemia: case report and literature review. Mediterr J Hematol Infect Dis. 2020;12(1):e2020005. https:\/\/doi.org\/10.4084\/mjhid.2020.005.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"10","key":"2181_CR24","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1007\/s10815-020-01907-2","volume":"37","author":"SJ Rios","year":"2020","unstructured":"Rios SJ, Mart\u00ednez-Montesinos L, Aroca C, Teruel-Montoya R, Ferrer-Mar\u00edn F. Successful ovarian stimulation and pregnancy in an infertile woman with chronic myeloid leukemia. J Assist Reprod Genet. 2020;37(10):2473\u20136. https:\/\/doi.org\/10.1007\/s10815-020-01907-2.","journal-title":"J Assist Reprod Genet"},{"issue":"4","key":"2181_CR25","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1111\/j.1365-2605.2007.00755.x","volume":"30","author":"M Nurmio","year":"2007","unstructured":"Nurmio M, Toppari J, Zaman F, Andersson AM, Paranko J, S\u00f6der O, et al. Inhibition of tyrosine kinases PDGFR and C-Kit by imatinib mesylate interferes with postnatal testicular development in the rat. Int J Androl. 2007;30(4):366\u201376; discussion 376. https:\/\/doi.org\/10.1111\/j.1365-2605.2007.00755.x.","journal-title":"Int J Androl"},{"issue":"4","key":"2181_CR26","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0253-7613.83107","volume":"43","author":"AM Prasad","year":"2011","unstructured":"Prasad AM, Ramnarayan K, Nalini K, Bairy KL. Effect of imatinib on the biochemical parameters of the reproductive function in male Swiss albino mice. Indian J Pharm. 2011;43(4):389\u201392. https:\/\/doi.org\/10.4103\/0253-7613.83107.","journal-title":"Indian J Pharm"},{"issue":"4","key":"2181_CR27","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1016\/j.reprotox.2010.12.056","volume":"31","author":"C Heim","year":"2011","unstructured":"Heim C, Minniear K, Dann CT. Imatinib has deleterious effects on differentiating spermatogonia while sparing spermatogonial stem cell self renewal. Reprod Toxicol (Elmsford, NY). 2011;31(4):454\u201363. https:\/\/doi.org\/10.1016\/j.reprotox.2010.12.056.","journal-title":"Reprod Toxicol (Elmsford, NY)"},{"issue":"8","key":"2181_CR28","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1002\/pbc.26028","volume":"63","author":"J Samis","year":"2016","unstructured":"Samis J, Lee P, Zimmerman D, Arceci RJ, Suttorp M, Hijiya N. Recognizing endocrinopathies associated with tyrosine kinase inhibitor therapy in children with chronic myelogenous leukemia. Pediatr Blood Cancer. 2016;63(8):1332\u20138. https:\/\/doi.org\/10.1002\/pbc.26028.","journal-title":"Pediatr Blood Cancer"},{"issue":"3","key":"2181_CR29","doi-asserted-by":"publisher","first-page":"1120.e1115","DOI":"10.1016\/j.fertnstert.2010.08.060","volume":"95","author":"S Mariani","year":"2011","unstructured":"Mariani S, Basciani S, Fabbri A, Agati L, Ulisse S, Lubrano C, et al. Severe oligozoospermia in a young man with chronic myeloid leukemia on long-term treatment with imatinib started before puberty. Fertil Steril. 2011;95(3):1120.e1115\u201327. https:\/\/doi.org\/10.1016\/j.fertnstert.2010.08.060.","journal-title":"Fertil Steril"},{"issue":"6","key":"2181_CR30","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1007\/s11523-017-0521-6","volume":"12","author":"X Chang","year":"2017","unstructured":"Chang X, Zhou L, Chen X, Xu B, Cheng Y, Sun S, et al. Impact of imatinib on the fertility of male patients with chronic myelogenous leukaemia in the chronic phase. Target Oncol. 2017;12(6):827\u201332. https:\/\/doi.org\/10.1007\/s11523-017-0521-6.","journal-title":"Target Oncol"},{"issue":"9373","key":"2181_CR31","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/s0140-6736(03)13554-4","volume":"361","author":"C Gambacorti-Passerini","year":"2003","unstructured":"Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Giraldi F, Mariani L, et al. Gynaecomastia in men with chronic myeloid leukaemia after imatinib. Lancet. 2003;361(9373):1954\u20136. https:\/\/doi.org\/10.1016\/s0140-6736(03)13554-4.","journal-title":"Lancet"},{"issue":"3","key":"2181_CR32","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1055\/s-0034-1372643","volume":"226","author":"JT Tauer","year":"2014","unstructured":"Tauer JT, Ulmer A, Glauche I, Jung R, Suttorp M. Long-term imatinib treatment does not cause testicular toxicity in male adolescents with chronic myeloid leukemia and in a juvenile rat model. Klin Padiatr. 2014;226(3):169\u201374. https:\/\/doi.org\/10.1055\/s-0034-1372643.","journal-title":"Klin Padiatr"},{"issue":"1","key":"2181_CR33","doi-asserted-by":"publisher","DOI":"10.4084\/mjhid.2014.028","volume":"6","author":"E Abruzzese","year":"2014","unstructured":"Abruzzese E, Trawinska MM, Perrotti AP, De Fabritiis P. Tyrosine kinase inhibitors and pregnancy. Mediterr J Hematol Infect Dis. 2014;6(1):e2014028. https:\/\/doi.org\/10.4084\/mjhid.2014.028.","journal-title":"Mediterr J Hematol Infect Dis"},{"issue":"3","key":"2181_CR34","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1200\/jco.2015.64.0102","volume":"34","author":"RS Benjamin","year":"2016","unstructured":"Benjamin RS, Casali PG. Adjuvant imatinib for GI stromal tumors: when and for how long? J Clin Oncol. 2016;34(3):215\u20138. https:\/\/doi.org\/10.1200\/jco.2015.64.0102.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2181_CR35","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1182\/blood-2006-03-011239","volume":"109","author":"P Rousselot","year":"2007","unstructured":"Rousselot P, Huguet F, Rea D, Legros L, Cayuela JM, Maarek O, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109(1):58\u201360. https:\/\/doi.org\/10.1182\/blood-2006-03-011239.","journal-title":"Blood"},{"issue":"9","key":"2181_CR36","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.3109\/10428194.2013.866662","volume":"55","author":"J Iqbal","year":"2014","unstructured":"Iqbal J, Ali Z, Khan AU, Aziz Z. Pregnancy outcomes in patients with chronic myeloid leukemia treated with imatinib mesylate: short report from a developing country. Leuk Lymphoma. 2014;55(9):2109\u201313. https:\/\/doi.org\/10.3109\/10428194.2013.866662.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2181_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. 2020;34(4):966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2.","journal-title":"Leukemia"},{"issue":"11","key":"2181_CR38","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1016\/s1470-2045(10)70233-3","volume":"11","author":"FX Mahon","year":"2010","unstructured":"Mahon FX, R\u00e9a D, Guilhot J, Guilhot F, Huguet F, Nicolini F, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol. 2010;11(11):1029\u201335. https:\/\/doi.org\/10.1016\/s1470-2045(10)70233-3.","journal-title":"Lancet Oncol"},{"issue":"3","key":"2181_CR39","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/sj.bmt.1705893","volume":"41","author":"J Liu","year":"2008","unstructured":"Liu J, Malhotra R, Voltarelli J, Stracieri AB, Oliveira L, Simoes BP, et al. Ovarian recovery after stem cell transplantation. Bone Marrow Transplant. 2008;41(3):275\u20138. https:\/\/doi.org\/10.1038\/sj.bmt.1705893.","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2181_CR40","doi-asserted-by":"publisher","first-page":"35","DOI":"10.2350\/08-03-0435.1","volume":"12","author":"RG Abellar","year":"2009","unstructured":"Abellar RG, Pepperell JR, Greco D, Gundogan F, Kostadinov S, Schwartz J, et al. Effects of chemotherapy during pregnancy on the placenta. Pediatr Dev Pathol. 2009;12(1):35\u201341. https:\/\/doi.org\/10.2350\/08-03-0435.1.","journal-title":"Pediatr Dev Pathol"},{"issue":"4","key":"2181_CR41","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/sj.jp.7211665","volume":"27","author":"MA Russell","year":"2007","unstructured":"Russell MA, Carpenter MW, Akhtar MS, Lagattuta TF, Egorin MJ. Imatinib mesylate and metabolite concentrations in maternal blood, umbilical cord blood, placenta and breast milk. J Perinatol: official journal of the California Perinatal Association. 2007;27(4):241\u20133. https:\/\/doi.org\/10.1038\/sj.jp.7211665.","journal-title":"J Perinatol: official journal of the California Perinatal Association"},{"issue":"3","key":"2181_CR42","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1080\/10428194.2017.1347929","volume":"59","author":"E Chelysheva","year":"2018","unstructured":"Chelysheva E, Turkina A, Polushkina E, Shmakov R, Zeifman A, Aleshin S, et al. Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment. Leuk Lymphoma. 2018;59(3):733\u20138. https:\/\/doi.org\/10.1080\/10428194.2017.1347929.","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"2181_CR43","doi-asserted-by":"publisher","first-page":"2535","DOI":"10.1038\/s41598-019-39134-0","volume":"9","author":"W Salem","year":"2019","unstructured":"Salem W, Li K, Krapp C, Ingles SA, Bartolomei MS, Chung K, et al. Imatinib treatments have long-term impact on placentation and embryo survival. Sci Rep. 2019;9(1):2535. https:\/\/doi.org\/10.1038\/s41598-019-39134-0.","journal-title":"Sci Rep"},{"key":"2181_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/jgo.18.00211","volume":"5","author":"I Madabhavi","year":"2019","unstructured":"Madabhavi I, Sarkar M, Modi M, Kadakol N. Pregnancy outcomes in chronic myeloid leukemia: a single center experience. J Glob Oncol. 2019;5:1\u201311. https:\/\/doi.org\/10.1200\/jgo.18.00211.","journal-title":"J Glob Oncol"},{"issue":"12","key":"2181_CR45","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.1182\/blood-2007-10-114900","volume":"111","author":"SM Pye","year":"2008","unstructured":"Pye SM, Cortes J, Ault P, Hatfield A, Kantarjian H, Pilot R, et al. The effects of imatinib on pregnancy outcome. Blood. 2008;111(12):5505\u20138. https:\/\/doi.org\/10.1182\/blood-2007-10-114900.","journal-title":"Blood"},{"issue":"5","key":"2181_CR46","doi-asserted-by":"publisher","first-page":"e197","DOI":"10.1097\/aog.0000000000002899","volume":"132","author":"ACOG Practice Bulletin No. 200","year":"2018","unstructured":"ACOG Practice Bulletin No. 200. Early Pregnancy Loss. Obstet Gynecol. 2018;132(5):e197\u2013207. https:\/\/doi.org\/10.1097\/aog.0000000000002899.","journal-title":"Obstet Gynecol"},{"issue":"3","key":"2181_CR47","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/s0015-0282(02)04694-0","volume":"79","author":"X Wang","year":"2003","unstructured":"Wang X, Chen C, Wang L, Chen D, Guang W, French J. Conception, early pregnancy loss, and time to clinical pregnancy: a population-based prospective study. Fertil Steril. 2003;79(3):577\u201384. https:\/\/doi.org\/10.1016\/s0015-0282(02)04694-0.","journal-title":"Fertil Steril"},{"issue":"4","key":"2181_CR48","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1056\/nejm198807283190401","volume":"319","author":"AJ Wilcox","year":"1988","unstructured":"Wilcox AJ, Weinberg CR, O\u2019Connor JF, Baird DD, Schlatterer JP, Canfield RE, et al. Incidence of early loss of pregnancy. N Engl J Med. 1988;319(4):189\u201394. https:\/\/doi.org\/10.1056\/nejm198807283190401.","journal-title":"N Engl J Med"},{"issue":"3","key":"2181_CR49","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/S0015-0282(16)58144-8","volume":"65","author":"MJ Zinaman","year":"1996","unstructured":"Zinaman MJ, Clegg ED, Brown CC, O\u2019Connor J, Selevan SG. Estimates of human fertility and pregnancy loss. Fertil Steril. 1996;65(3):503\u20139.","journal-title":"Fertil Steril"},{"key":"2181_CR50","unstructured":"Centers for Disease Control and Prevention (CDC). Update on overall prevalence of major birth defects\u2013Atlanta, Georgia, 1978\u20132005. MMWR Morb Mortal Wkly Rep. 2008;57(1):1\u20135."},{"issue":"4","key":"2181_CR51","doi-asserted-by":"publisher","first-page":"324","DOI":"10.3816\/CLM.2009.n.064","volume":"9","author":"S Cole","year":"2009","unstructured":"Cole S, Kantarjian H, Ault P, Cort\u00e9s JE. Successful completion of pregnancy in a patient with chronic myeloid leukemia without active intervention: a case report and review of the literature. Clin Lymphoma Myeloma. 2009;9(4):324\u20137. https:\/\/doi.org\/10.3816\/CLM.2009.n.064.","journal-title":"Clin Lymphoma Myeloma"},{"issue":"3","key":"2181_CR52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1159\/000381806","volume":"24","author":"N Jain","year":"2015","unstructured":"Jain N, Sharma D, Agrawal R, Jain A. A newborn with teratogenic effect of imatinib mesylate: a very rare case report. Med Princ Pract. 2015;24(3):291\u20133. https:\/\/doi.org\/10.1159\/000381806.","journal-title":"Med Princ Pract"},{"issue":"7","key":"2181_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.ss6907a1","volume":"69","author":"K Kortsmit","year":"2020","unstructured":"Kortsmit K, Jatlaoui TC, Mandel MG, Reeves JA, Oduyebo T, Petersen E, et al. Abortion Surveillance - United States, 2018. Morbidity and mortality weekly report. Surveill Summ (Washington, DC: 2002). 2020;69(7):1\u201329. https:\/\/doi.org\/10.15585\/mmwr.ss6907a1.","journal-title":"Surveill Summ (Washington, DC: 2002)"},{"issue":"2 Suppl 2","key":"2181_CR54","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1053\/shem.2003.50038","volume":"40","author":"ML Hensley","year":"2003","unstructured":"Hensley ML, Ford JM. Imatinib treatment: specific issues related to safety, fertility, and pregnancy. Semin Hematol. 2003;40(2 Suppl 2):21\u20135. https:\/\/doi.org\/10.1053\/shem.2003.50038.","journal-title":"Semin Hematol"},{"issue":"7","key":"2181_CR55","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1200\/jco.2005.04.6557","volume":"24","author":"P Ault","year":"2006","unstructured":"Ault P, Kantarjian H, O\u2019Brien S, Faderl S, Beran M, Rios MB, et al. Pregnancy among patients with chronic myeloid leukemia treated with imatinib. J Clin Oncol. 2006;24(7):1204\u20138. https:\/\/doi.org\/10.1200\/jco.2005.04.6557.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2181_CR56","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s11845-014-1084-5","volume":"184","author":"A Mukhopadhyay","year":"2015","unstructured":"Mukhopadhyay A, Dasgupta S, Kanti Ray U, Gharami F, Bose CK, Mukhopadhyay S. Pregnancy outcome in chronic myeloid leukemia patients on imatinib therapy. Ir J Med Sci. 2015;184(1):183\u20138. https:\/\/doi.org\/10.1007\/s11845-014-1084-5.","journal-title":"Ir J Med Sci"},{"issue":"7","key":"2181_CR57","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1080\/10428194.2018.1551533","volume":"60","author":"M Lasica","year":"2019","unstructured":"Lasica M, Willcox A, Burbury K, Ross DM, Branford S, Butler J, et al. The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia. Leuk Lymphoma. 2019;60(7):1796\u2013802. https:\/\/doi.org\/10.1080\/10428194.2018.1551533.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2181_CR58","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1111\/j.1365-2141.2007.06542.x","volume":"137","author":"K Ramasamy","year":"2007","unstructured":"Ramasamy K, Hayden J, Lim Z, Mufti GJ, Ho AY. Successful pregnancies involving men with chronic myeloid leukaemia on imatinib therapy. Br J Haematol. 2007;137(4):374\u20135. https:\/\/doi.org\/10.1111\/j.1365-2141.2007.06542.x.","journal-title":"Br J Haematol"},{"issue":"3","key":"2181_CR59","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.leukres.2007.07.022","volume":"32","author":"M Breccia","year":"2008","unstructured":"Breccia M, Cannella L, Montefusco E, Frustaci A, Pacilli M, Alimena G. Male patients with chronic myeloid leukemia treated with imatinib involved in healthy pregnancies: report of five cases. Leuk Res. 2008;32(3):519\u201320. https:\/\/doi.org\/10.1016\/j.leukres.2007.07.022.","journal-title":"Leuk Res"},{"issue":"1","key":"2181_CR60","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2014.10.002","volume":"39","author":"H Alizadeh","year":"2015","unstructured":"Alizadeh H, Jaafar H, Rajnics P, Khan MI, Kajt\u00e1r B. Outcome of pregnancy in chronic myeloid leukaemia patients treated with tyrosine kinase inhibitors: short report from a single centre. Leuk Res. 2015;39(1):47\u201351. https:\/\/doi.org\/10.1016\/j.leukres.2014.10.002.","journal-title":"Leuk Res"},{"issue":"2","key":"2181_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s00404-016-4262-z","volume":"295","author":"P Carlier","year":"2017","unstructured":"Carlier P, Markarian M, Bernard N, Lagarce L, Dautriche A, B\u00e9n\u00e9 J, et al. Pregnancy outcome among partners of male patients receiving imatinib, dasatinib or nilotinib in chronic myeloid leukemia: reports collected by the French network pharmacovigilance centers. Arch Gynecol Obstet. 2017;295(2):269\u201371. https:\/\/doi.org\/10.1007\/s00404-016-4262-z.","journal-title":"Arch Gynecol Obstet"},{"issue":"2","key":"2181_CR62","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.htct.2018.10.001","volume":"41","author":"AC Moura","year":"2019","unstructured":"Moura AC, Delamain MT, Duarte GBO, Lorand-Metze I, Souza CA, Pagnano KBB. Management of chronic myeloid leukemia during pregnancy: a retrospective analysis at a single center. Hematol Transfus Cell Ther. 2019;41(2):125\u20138. https:\/\/doi.org\/10.1016\/j.htct.2018.10.001.","journal-title":"Hematol Transfus Cell Ther"},{"issue":"11","key":"2181_CR63","doi-asserted-by":"publisher","first-page":"e1141","DOI":"10.1634\/theoncologist.2019-0109","volume":"24","author":"X Dou","year":"2019","unstructured":"Dou X, Qin Y, Huang X, Jiang Q. Planned pregnancy in female patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor Therapy. Oncologist. 2019;24(11):e1141\u20137. https:\/\/doi.org\/10.1634\/theoncologist.2019-0109.","journal-title":"Oncologist"},{"issue":"1","key":"2181_CR64","doi-asserted-by":"publisher","first-page":"e2018027","DOI":"10.4084\/mjhid.2018.027","volume":"10","author":"E Chelysheva","year":"2018","unstructured":"Chelysheva E, Aleshin S, Polushkina E, Shmakov R, Shokhin I, Chilov G, et al. Breastfeeding in patients with chronic myeloid leukaemia: case series with measurements of drug concentrations in maternal milk and literature review. Mediterr J Hematol Infect Dis. 2018;10(1):e2018027. https:\/\/doi.org\/10.4084\/mjhid.2018.027.","journal-title":"Mediterr J Hematol Infect Dis"}],"container-title":["Journal of Assisted Reproduction and Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10815-021-02181-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10815-021-02181-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T23:42:50Z","timestamp":1630712570000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10815-021-02181-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,7]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["2181"],"URL":"https:\/\/doi.org\/10.1007\/s10815-021-02181-6","relation":{},"ISSN":["1058-0468","1573-7330"],"issn-type":[{"value":"1058-0468","type":"print"},{"value":"1573-7330","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,7]]},"assertion":[{"value":"18 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}